NCT02383940 - Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG

Sotagliflozin

Sotagliflozin 400 mg, once daily before the first meal of the day

DRUG

Placebo

Placebo, once daily before the first meal of the day

Trial Locations (15)

14222

Lexicon Investigational Site, Buffalo

28401

Lexicon Investigational Site, Wilmington

30076

Lexicon Investigational Site, Roswell

30318

Lexicon Investigational Site, Atlanta

33401

Lexicon Investigational Site, West Palm Beach

33612

Lexicon Investigational Site, Tampa

46202

Lexicon Investigational Site, Indianapolis

70121

Lexicon Investigational Site, New Orleans

78749

Lexicon Investigational Site, Austin

80045

Lexicon Investigational Site, Aurora

84107

Lexicon Investigational Site, Salt Lake City

92780

Lexicon Investigational Site, Tustin

06519

Lexicon Investigational Site, New Haven

04210

Lexicon Investigational Site, Auburn

02215

Lexicon Investigational Site, Boston